Author
Listed:
- Sirma Tomos
(Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania, Railway Hospital, Constanta, Romania)
- Cristina-Luiza Erimia
(Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania)
- Doina Margaritti
(Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania)
- Florica Busuricu
(Ovidius University of Constanta, Faculty of Pharmacy, Constanta, Romania)
Abstract
Severe acute respiratory syndrome (SARS CoV2) is an unparalleled challenge for the global medical community. Although the main clinical manifestation is pulmonary, with variations ranging from asymptomatic to mild flu-like illness to severe pneumonia and acute respiratory distress syndrome with potential fatality. The essential mechanism consists of the binding of the virus to ACE2 receptors through a viral envelope protein (protein S or SPIKE) followed by the appearance of a serum protease TMPRSS2 which mediates the binding of the virus at the cellular level. Because ACE2 is a cell membrane peptidase in the lungs, heart, blood vessels, kidneys, brain and gastrointestinal tract, COVID19 infections can occur at any of these levels. All ACE2-expressing cells are at risk of infection. Currently, viral pericarditis associated with both SARS CoV2 infection and vaccination against this virus is becoming more and more common, regardless of the vaccine used. Since April 2021 in the US there have been over 1000 reports in VAERS of myocarditis and post-vaccination pericarditis m RNA Covid-19 (BioNTech, Modern). Although the frequency of myocarditis and pericarditis was rare post-vaccination - 0.0018% of cases reported between December 2020 and July 2021 - the number of cases is certainly much higher, these complications being underdiagnosed, and therefore incorrectly managed and treated[1]. In fact, government organizations also considered these complications, on June 23, 2021 the safety committee of the US Centers for Disease Control and Prevention stated that there is a likely association between Pfizer - BioNTech and Moderna vaccines and myocarditis and pericarditis in some young people (16 -24 years), but that the benefits clearly outweigh the risks[2] As a result of all these signals, the US Food and Drug Administration said it will add this risk to the mRNA vaccine fact sheets, although it considers that such complications are "extremely rare" and that "most cases have been mild"[3].
Suggested Citation
Download full text from publisher
Corrections
All material on this site has been provided by the respective publishers and authors. You can help correct errors and omissions. When requesting a correction, please mention this item's handle: RePEc:tec:bioche:ojs:10263. See general information about how to correct material in RePEc.
If you have authored this item and are not yet registered with RePEc, we encourage you to do it here. This allows to link your profile to this item. It also allows you to accept potential citations to this item that we are uncertain about.
We have no bibliographic references for this item. You can help adding them by using this form .
If you know of missing items citing this one, you can help us creating those links by adding the relevant references in the same way as above, for each refering item. If you are a registered author of this item, you may also want to check the "citations" tab in your RePEc Author Service profile, as there may be some citations waiting for confirmation.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: Anna Maria Golita (email available below). General contact details of provider: .
Please note that corrections may take a couple of weeks to filter through
the various RePEc services.